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Abstract 13 
Background: Published LC-MS/MS methods are not sensitive enough to quantify 14 
endogenous levels of glucagon. Results: A UHPLC-MS/MS (SRM) method for the 15 
quantitation of endogenous levels glucagon was successfully developed and qualified. A 16 
novel 2D extraction procedure was used to reduce matrix suppression, background noise 17 
and interferences. Glucagon levels in samples from healthy volunteers were found to agree 18 
with RIA derived literature values. Bland-Altman analysis showed a concentration-dependent 19 
positive bias of the LC/MS-MS assay versus an RIA.  Both assays produced similar 20 
pharmacokinetic profiles, both of which were feasible considering the nature of the study. 21 
Conclusions: Our method is the first peer reviewed LC-MS/MS method for the quantitation 22 
of endogenous levels of glucagon, and offers a viable alternative to RIA based approaches.  23 
Introduction 24 
Glucagon is a 29 amino acid peptide which is one of multiple hormones that modulates 25 
glucose production or utilisation to regulate blood glucose levels. It is also a biomarker for 26 
pathologies such as diabetes, pancreatic cancer or certain neuroendocrine tumours [1]. It is 27 
known to be degraded by peptidases such as dipeptidyl peptidase IV [2][3] and 28 
consequently blood samples are typically collected in tubes containing protease inhibitors. 29 
Endogenous glucagon levels in healthy patients are reported between 25-80 pg/mL, which 30 
may be raised by about 10 pg/mL in pancreatic cancer patients, and can reach up to 160 31 
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pg/mL in diabetic patients [1]. Following treatments using glucagon infusion levels can reach 32 
~906 pg/mL [4]. Glucagon concentrations are routinely measured using radioimmunoassay 33 
(RIA) based approaches, however these assays can be time consuming to perform (up to 3 34 
days) and the kits hasuppleve limited lifetimes (e.g. 2 months). In addition they can suffer 35 
from poor precision and accuracy, as there is potential for cross reactivity with similar 36 
compounds or inactive degradation fragments leading to inaccurate quantitation [5][6][7]. For 37 
example, whilst a comparison between two glucagon immunoassays resulted in a high 38 
correlation (R=0.97), the concentrations between individual samples differed by 2-4 fold [8]. 39 
The radioactive nature of RIAs also necessitates additional health and safety precautions 40 
during set-up, and specialised disposal of radioisotopes.  41 
A LC-MS/MS assay would have the potential to circumvent such problems [9], and may offer 42 
additional benefits such as a reduced sample volume and a higher throughout. However, 43 
published LC-MS/MS methods [10][11] are not sensitive enough to detect endogenous 44 
glucagon levels. As described in a recent review paper [12] the lowest reported LLOQ in the 45 
peer reviewed literature is 250 pg/mL [11],  although assays of 100 pg/mL [13] and 10 pg/mL 46 
[14] have been described at recent conferences.  47 
Furthermore, as glucagon is produced endogenously, this presents additional experimental 48 
challenges as an authentic analyte free matrix cannot be obtained to construct calibration 49 
standards. Either a standard addition, surrogate analyte, or a surrogate matrix approach 50 
must therefore be used [15][16].  51 
In the standard addition based approach, analyte is spiked on top of the authentic matrix to 52 
create a calibration line, which is extrapolated to measure concentrations below the matrix’s 53 
endogenous value. However the USA FDA Guidance for Bioanalytical Method Validation 54 
[17] actively discourages the extrapolation of calibration curves beyond their range. The 55 
surrogate analyte based approach uses an analogue to the analyte in place of the analyte 56 
itself in calibration samples. As this will have a Selected Reaction Monitoring (SRM) 57 
transition unique from the authentic analyte these can be prepared in authentic biological 58 
matrix [15] . However, this approach requires the relationship between the authentic and 59 
surrogate analyte to be thoroughly investigated, the approach is not commonly used, and is 60 
not considered in the FDA [17] or EMA guidelines [18]. Alternatively, in the surrogate matrix 61 
approach, calibration lines are constructed by spiking analyte into a surrogate matrix. QCs 62 
can be prepared in actual sample matrix, and the accuracy calculated to demonstrate the 63 
absence of a matrix effect. Surrogate matrices may be the authentic matrix stripped of 64 
analyte (e.g. by charcoal [16] or immuno-afffinity methods [19]) or an alternative matrix (e.g. 65 
protein buffers, dialysed serum [20]). Although not ideal, the EMA Guideline on bioanalytical 66 
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method validation [18] concedes that such an approach may be necessary for endogenous 67 
analyte quantitation, and therefore this is the approach we adopted.  68 
 69 
This article outlines the first peer reviewed high throughput UHPLC-MS/MS (SRM) based 70 
approach capable of quantifying endogenous levels of glucagon from human plasma.  The 71 
high throughput nature of the assay is due to its ability to relatively quickly analyse large 72 
numbers of samples.  This is enabled by an extraction procedure that is relatively quick, 73 
simple, and cheap in comparison to many immunochemistry based approaches  [21], and 74 
which can analyse large number of samples (60) within an analytical batch. In addition, 75 
UHPLC is used to minimise sample run times [22].A calibration range of 25–1000 pg/mL is 76 
qualified, making the assay suitable for measuring both endogenous levels of glucagon and 77 
elevated levels following treatments. Consequently the assay can be used for both 78 
biomarker (PD, Pharacodymaic) and Pharmacokinetic (PK) analysis. However, the 79 
calibration range could be easily truncated if only endogenous level analysis (PD) is 80 
required. In addition we present the first comparison of glucagon concentrations determined 81 
by an LC-MS/MS assay and a traditional RIA method using a large number of clinical 82 
samples derived from a physiological study of glucagon’s actions in the body (n=88). 83 
The assay‘s performance has been evaluated using experiments described in the latest 84 
EMA [18] and FDA [17] guidance and in accordance to the principles of GCP [23].  85 
Key Terms 86 
Radioimmunoassay (RIA) - A highly sensitive technique used to measure concentrations of 87 
antigens (e.g. peptides) by use of antibodies. Pre-bound radioactively labelled antigens are 88 
displaced by non-radioactive antigens from a sample. Monitoring the change in radioactivity 89 
allows quantitation.  90 
UHPLC-MS/MS (SRM) – An analytical methodology that combines the use of ultra-high 91 
performance liquid chromatographic (UHPLC) separations with sensitive mass spectrometer 92 
selected reaction monitoring (SRM). Traditionally used for small molecule quantitation, but 93 
increasingly used for the quantitation of biological molecules (e.g. peptides).94 
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Experimental  95 
Chemicals and materials 96 
Certified human glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) was obtained from 97 
EDQM (Strasbourg, France) and the analog internal standard (IS) (des-thr7-glucagon) 98 
(HSQGTFSDYS KYLDSRRAQDFVQWLMNT) from Bachem (Bubendorf, Switzerland). This  99 
internal standard has given suitable performance in LC-MS/MS glucagon assays   [13] [14], 100 
and it avoids the expense of synthesising a heavy labelled internal standard. Water was 101 
produced by a Triple Red water purifier (Buckinghamshire, U.K.). BD glass collection tubes 102 
(5 mL) containing K3 EDTA anticoagulant and 250 Kallikrein Inhibitor Units (KIU) of Aprotinin 103 
were obtained from BD (Oxford, UK). Following collection, tubes were placed on ice, then 104 
centrifuged at 2300 x g for 10 minutes to obtain plasma, which was stored at -80C when not 105 
in use. All chemicals and solvents were HPLC or analytical reagent grade and purchased 106 
from commercial vendors. 107 
Instrumentation: LC-MS/MS 108 
The LC-MS/MS system consisted of a Waters Acquity UPLC system (Waters Corporation, 109 
Massachusetts, USA) coupled to an AB SCIEX 5500 QTRAP (Applied Biosystems / MDS 110 
SCIEX, Ontario, Canada) with an electrospray ion source. Data acquisition and processing 111 
were performed using Analyst 1.5.2 (Applied Biosystems/ MDS SCIEX). The majority of the 112 
chromatograms were integrated using fully automated settings. A minority had their 113 
integration settings (peak selection, peak splitting factor, noise percentage) altered to ensure 114 
appropriate and consistent integration. No samples were integrated using manual integration 115 
mode. 116 
Glucagon was separated on a Waters UPLC BEH C18 1.7 µm (2.1 x 100 mm) column 117 
maintained at 60 C. The mobile phase consisted of (A) 0.2% formic acid (FA) in acetonitrile 118 
(MeCN) and (B) 0.2% FA (aq). The gradient for separation was 22–32% A over 2 minutes. 119 
The column was then cleaned with 95% A for approximately 1 minute then 22% A for 120 
approximately 4 minutes. The flow rate was 0.8 mL/min and the total run time 7.1 minutes. 121 
The mass spectrometer was operated in positive ion mode with an electrospray voltage of 122 
5500 V, an entrance potential of 10 V, and a declustering potential of 70 V. The source 123 
temperature was 600C, the curtain gas 40 Psi, and the desolvation gases, GS1 and GS2, 124 
were set at 60 psi and 40 psi respectively. Quantitation was performed using the selected 125 
reaction monitoring (SRM) transitions 697.5693.8 and 677.2673.8 for glucagon and the 126 
internal standard respectively. The N2 collision gas was set to medium and both transitions 127 
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used collision energies of 15 V and collision exit cell potentials of 13 V. The Q1 and Q3 128 
quadruples were both operated at unit resolution. 129 
Preparation of stock, standards and QC MED and HIGH plasma samples 130 
1 mg/mL stock solutions of glucagon and glucagon internal standard were prepared in 131 
borosilicate vials using surrogate matrix [Methanol (MeOH): H2O: Formic acid (FA): Bovine 132 
serum albumin (BSA), (20:80:0.1:0.1, v/v/v/w)]. Glucagon working solutions were prepared 133 
by dilution with this solvent to create nine calibration standard spiking solutions (125, 225, 134 
375, 500, 1000, 2000, 3000, 4500, 5000 pg/mL), and four quality control spiking solutions 135 
(125, 250, 10000, 75000 pg/mL). Additional calibration standard and QC spiking solutions at 136 
75 and 50 pg/mL were also prepared for the assessment of assay performance at the 10 137 
and 15 pg/mL levels.  Internal standard working solution (ISWS) was similarly prepared at 20 138 
ng/mL. The stock and working solutions were prepared to a volume of 10 mL and were 139 
stored at -20 C when not in use. QC MED and QC HIGH plasma samples were prepared by 140 
diluting the appropriate spiking solution 100 fold with plasma to create samples at 100 and 141 
750 pg/mL respectively.  These were either used immediately, or stored at -80 C prior to 142 
use.  143 
Extraction method development & surrogate matrix quantitation 144 
Additional details of the extraction method development experiments described are provided 145 
in the supplementary information. In summary: 146 
Protein precipitation optimisation The following precipitation solvents were investigated; 147 
Acetonitrile (MeCN), MeCN:H2O (50:50,v/v), and MeCN:H2O (75:25, v/v). Each solvent was 148 
investigated with and without 0.1% formic acid. In addition MeCN: H2O: NH3 (75:25:0.1, 149 
v/v/v) was investigated. 150 
Solid phase extraction optimisation Extraction efficiencies of the MAX, MCX, and WCX 151 
phases from a 96 well Oasis sorbent selection plate (10 mg) (Waters Corporation) and from 152 
a size exclusion hydrophobic (SEH) Bond Elut Plexa 96 round-well (30 mg) plate (Agilent 153 
Technologies, California, USA) were evaluated. The Oasis extraction used generic 154 
conditions for peptide analysis based on those provided by the manufacturer, whilst we used 155 
our in house generic conditions for the Plexa evaluation. 156 
Surrogate matrix quantitation- The calibration standard spiking solutions described above 157 
were diluted 5 fold with surrogate matrix. 400 µL aliquots were  then extracted according to 158 
the procedure below. The matrices investigated were H2O, MeOH: H2O:FA:BSA 159 
(20:80:0.1:0.1, v/v/v/w), 6% BSA (aq) and 6% rat plasma (aq). 160 
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Extraction method for validation 161 
Plasma sample (aprotinin stabilised, K3 EDTA) (400 µL) was placed into a 5 mL 162 
polypropylene tube and 20 µL of ISWS was added to all non-blank samples. The samples 163 
were briefly vortex mixed, precipitated using 3.2 mL of MeCN:H2O:NH3 (72:25:0.1,v/v/v), 164 
vortex mixed again, and then centrifuged for 10 minutes at 2300 x g. The supernatant was 165 
transferred to a new tube and evaporated to dryness overnight under vacuum. Samples 166 
were reconstituted in 800 µL 2% NH3 (aq) and then vortex mixed. A Bond Elut Plexa 96 167 
round-well solid phase extraction (SPE) plate (30 mg) was conditioned using 1 mL MeOH, 168 
then equilibrated with 1 mL H20. The samples were loaded, washed with 1 mL 5% MeOH 169 
(aq), eluted with 2 x 225 µL MeCN:H2O:FA (75:25:0.1, v/v/v), and then evaporated under 170 
nitrogen at 40C, before being reconstituted in 200 µL 0.2% FA (aq).  171 
Calibration standards, QC LLOQs and QC LOWs were then prepared freshly for each batch 172 
by spiking 80 µL of the appropriate spiking solution into the plate, along with 20 µL of ISWS 173 
and 100 µL surrogate matrix. Taking into account the 2-fold concentration experienced by 174 
plasma samples (400 µL of plasma sample is reconstituted into 200 µL of solvent) this gives 175 
final calibration levels of 25, 45, 75, 100, 200, 400, 600, 900, and 1000 pg/mL, and final QC 176 
levels of 25 and 50 pg/mL. The plate was centrifuged for 10 minutes at 2300 x g, and 50 µL 177 
of sample injected on to the LC-MS/MS system for analysis. 178 
Validation Experiments 179 
The validation experiments chosen were based on those described in the latest EMA 180 
guidance [18]. Calibration standards were analysed in duplicate with each batch. Data was 181 
imported into Watson LIMS 7.2 (Thermo Fisher Scientific Inc, Massachusetts, USA) and 182 
linear regression with 1/x2 weighting was applied to the peak area ratios-concentration plot 183 
for the construction of calibration lines. The precision and accuracy of the method was 184 
determined by analysis of replicate (n=6) QC samples at four different concentrations (25, 185 
50, 100, and 750 pg/mL), and was assessed within a batch (intra-batch, n = 6 replicates) 186 
and between batches (inter-batch, 3 batches). The ability to dilute was assessed by diluting 187 
an over range dilution sample (7500 pg/mL) 10-fold with blank plasma. Carryover effects 188 
were evaluated by injection of blank samples immediately after injection of the highest point 189 
in the calibration range.  190 
Selectivity was assessed by qualitatively examining chromatograms from six independent 191 
control matrix samples for the presence of potentially interfering peaks. It was not feasible to 192 
monitor multiple charge states or SRM transitions to further ensure selectivity as only the 193 
selected transition demonstrated sufficient sensitivity at the endogenous concentration .The 194 
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modification of analyte and internal standard responses to the presence of matrix was also 195 
determined in such samples. These were extracted and post spiked at either the medium or 196 
high level, and compared to the mean response from samples in surrogate matrix (minimum 197 
n=6). The effect of haemolysed (3%) plasma and hyperlipidaemic plasma (~4 mmol/L of 198 
triglycerides) upon on quantitation was investigated by preparing QCs in these matrices at 199 
the medium and high level (n=6 replicates). Recovery of the analyte was evaluated by 200 
comparing the analytical results for extracted analyte samples at the medium and high level 201 
with unextracted analyte samples that represent 100% recovery.  202 
 203 
The stability of the glucagon in aprotinin stabilised human plasma was evaluated at the 204 
medium and high concentrations in replicate (n=6). Stability was assessed after  205 
6 hr 20 min on ice (4 C), after storage for 11 and 75 days at -20°C, and for 7, 11, 51, and 64 206 
days at -80°C. Similarly stability was assessed after 4 freeze-thaw cycles from -20 C to 4 C 207 
and also 4 freeze cycles from -80 C to 4 C.   Stability was similarly assessed in whole 208 
blood following storage on ice for 1 hour. The ability to re-inject sample extracts at medium 209 
and high concentrations was assessed after storage at +4°C for 6 days. The stability of the 210 
stock solution was assessed after storage at -20C for 66 days and that of LLOQ and ULOQ 211 
working solutions after 163 days at -20C. 212 
 213 
All results are quoted from batches where the standards and QCs passed our prospectively 214 
defined acceptance criteria, which were based on the EMA and FDA guidelines. These 215 
required that at least 75% of standards in each batch had back calculated accuracy within 216 
15% (20% at the LLOQ) of the nominal concentration, with standards outside these criteria 217 
excluded from the regression. QCs in precision and accuracy batches needed to have mean 218 
intra-batch accuracy within 20% of the nominal concentration, and intra-batch precision that 219 
did not exceed 20%. In other batches at least 2/3 of the individual QCs had accuracy within 220 
20% of the nominal concentration, with at least one QC passing criteria at each level. 221 
Although the guidelines suggest a 15% criteria (20% at the LLOQ) should be applied to QC 222 
performance, they state it can be widened prospectively in special cases. We felt it was 223 
justified to raise the QC acceptance criteria to 20% (CV and RE) due to the surrogate matrix 224 
nature of the assay. The 20% (RE) acceptance criteria was also applied to plasma, blood 225 
and extract stability experiments, as well as to the assessment of the matrix effect in 226 
different individuals (matrix factor ratio) and of the effect of haemolysed or hyperlipidaemic 227 
plasma. 228 
 229 
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Collection of samples from volunteers to assess endogenous glucagon concentrations  230 
Plasma was collected from 12 healthy males and 12 healthy females using glass collection 231 
tubes containing K3 EDTA and aprotinin, as described above. Glucagon levels were 232 
determined using the qualified LC-MS/MS method. Plasma was collected at the start of the 233 
working day and volunteers were not asked to change their usual eating regime. 234 
 235 
Collection of physiological study samples 236 
Physiological study samples (n=117) were collected by Imperial College London. The 237 
samples originated from 7 different individuals who were each infused with a glucagon 238 
solution at either 16 or 20 pmol/kg/min for 12 hours subcutaneously. Blood samples at 239 
various time points were collected in 5 mL lithium heparin collection tubes containing 1000 240 
KIU of Aprotinin, spun down in a cold centrifuge within 5 to 10 mins of collection, and then 241 
stored at -20 C.   242 
Analysis of physiological study samples  243 
A selection of the physiological study samples (n=100) were analysed by LGC using the LC-244 
MS/MS method described above. Additional QCs prepared in aprotinin stabilised plasma  245 
with lithium heparin anticoagulant were analysed to ensure assay performance in the sample 246 
matrix. 38 of the study samples were analysed over the calibration range 25–1000 pg/mL, 247 
whilst the remainder were analysed over the calibration range 10–1000 pg/mL. For these 248 
samples additional calibration points and QCs were included at the 10 and 15 pg/mL levels 249 
to evaluate assay performance. Samples (n=105) were also analysed by Imperial College 250 
using their established radioimmunoassay method over the calibration range 5 -1000 pg/mL, 251 
which is directed against the C-terminal region of glucagon [24][25]. Samples were analysed 252 
upon their first freeze-thaw. 253 
 254 
Results and discussion 255 
Method development 256 
Analysis of endogenous levels of glucagon by LC-MS/MS poses a significant technical 257 
challenge. Not only are the low endogenous concentrations difficult to measure, an 258 
endogenous analyte quantitation strategy must be used, and stability issues must be 259 
addressed.  260 
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Extensive assay optimisation was therefore performed to obtain the low 25 pg/mL LLOQ. A 261 
QTRAP mass spectrometer was used in SRM mode, and parameters were optimised. 262 
UHPLC was chosen for chromatographic separation because it results in greater efficiencies 263 
[26] and/or shorter runtimes [27]  than the HPLC commonly used for such separations. The 264 
greater efficiency can lead to lower matrix effects due to improved separation from matrix 265 
suppressants [28]  and to higher sensitivities due to sharper peak shapes [22].  266 
The [M+5H+] 5+ ion was found to give the highest intensity during MS method development 267 
(Figure 1a), although other studies have found the [M+4H+]+4 to be optimal [11][10]. MS2 268 
experiments showed that showed that the ionic species generated by ESI of glucagon were 269 
able to absorb substantial collision energy without undergoing major fragmentations, as 270 
demonstrated previously [10] (Figure 1b).  As also reported [13][12] an SRM transition  271 
corresponding to the loss of ammonia ([M+5H+]+5/[M+5H+-NH3]
+5 was found to be optimal.  272 
Although this is not a particularly specific transition, the intensity was significantly greater 273 
than other transitions and was therefore chosen; selectivity was fully investigated during the 274 
validation. Resolution settings for Q1 and Q3 were optimal at unit-unit, rather than high-high 275 
as reported by others [11].  The optimal ion pairs of the transitions were 697.5/693.8, which 276 
corresponds to a 18.5 Da loss. The small difference between our optimal pair, and that 277 
previously reported (697.6/694.2) [13][12] is attributed to the resolution limitations of the 278 
mass spectrometer used [29], as is the difference between the theoretical mass  loss of 279 
ammonia (17 Da) and that observed (18.5 Da). 280 
 281 
 282 
Figure 1a (top)-Glucagon full scan MS spectrum A mass window of 400 -1250 m/z was isolated.  283 
b)(bottom) MS spectrum of production ion scans (Parent= 697.5, CE= 25 V) 284 
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 285 
A relatively large 400 µL plasma volume was chosen for extraction, to enable concentration 286 
of extracts to achieve higher sensitivities. The volume does, however, compare well to the  287 
2 x 200 µL typically required for RIA methods. Initially, protein precipitation based extraction 288 
techniques were investigated, as they are quick and cheap, and are amenable to automation 289 
and high throughput analysis. Additionally, pure acetonitrile precipitation has been previously 290 
selected for glucagon extractions [10] [11]. We have previously demonstrated that diluting 291 
acetonitrile with various proportions of water can lead to more specific extractions [30], as 292 
can the addition of acids or bases to due to the differences between the isoelectric points 293 
(pI) of the proteins or peptides of interest and the background proteins [31]. Precipitation 294 
solvents containing various proportions of acetonitrile, water, acid and base were 295 
investigated, with MeCN:H2O:NH3 (75:25:0.1,v/v/v) giving the best response. However, in all 296 
cases background noise and interferences were relatively high, as was matrix suppression. 297 
It was therefore decided to investigate solid phase extraction (SPE) based approaches, as 298 
these should lead to cleaner samples with reduced background noise and interferences. 299 
These studies are described in the supplementary information.  300 
Combining protein precipitation with size exclusion hydrophobic (SEH) SPE was found to 301 
reduce the on column matrix effects, whilst providing adequate recovery. To our knowledge 302 
this is the first time protein precipitation has been combined with SEH SPE for quantitative 303 
peptide analysis, although protein precipitation has been combined with other SPE phases 304 
for this purpose[32].  Due to the satisfactory performance of this extraction methodology, 305 
alternatives such as immunoaffinity enrichment were not investigated [33].   306 
 307 
Various UHPLC gradients were investigated to further reduce matrix build-up on the column 308 
and it was found that a 4 minute flush at the starting conditions gave the best performance. 309 
This gradient combined with the 2D extraction methodology significantly increased the 310 
robustness of the assay. 311 
Glucagon is known to be degraded by the blood enzymes and consequently sample 312 
stabilisation is required [2] . The enzyme inhibitor aprotinin was used to reduce degradation 313 
and samples were extracted on ice. As there have been reports of enzyme inhibitors 314 
interfering with peptide quantitation [34] assay performance was closely monitored during 315 
the validation for any such issues.  316 
  317 
Page 11 of 27 
 
Surrogate matrix quantitation 318 
Several mixtures were screened for their suitability as surrogate matrices. A dilute buffer 319 
matrix was evaluated, as such matrices have been shown to be suitable for some assays. 320 
[35] [19]. A buffer solution containing a relatively high percentage of BSA was also evaluated 321 
to minimise any non-specific analyte binding that may occur. In addition a diluted rat plasma 322 
matrix was chosen to investigate whether biological matricies improved assay performance.     323 
 The dilute buffer matrix, Water and MeOH: H2O: FA: BSA (20:80:0.1:0.1, v/v/v/w), resulted 324 
in low signals following extraction, which is attributed to non-specific binding of glucagon to 325 
plastic consumables used during the extraction procedure, as has been described previously 326 
[10]. The 6% BSA (aq) matrix, selected to minimise non-specific binding in solvent led to a 327 
very high background noise, whilst the 6% rat plasma (aq) led to poor calibration line 328 
accuracy against prepared concentrations. It was therefore decided to use MeOH: H2O: FA: 329 
BSA (20:80:0.1:0.1, v/v/v/w) as the surrogate matrix, but not to extract samples prepared in 330 
this, in order to prevent large losses by nonspecific binding. Whilst plasma samples require 331 
extraction, their high protein content prevents binding and the use of an internal standard 332 
was expected to take into account recovery differences between the surrogate matrix 333 
calibrants (which will necessarily have recovery of 100% for the analyte and IS) and the 334 
extracted plasma samples. The internal standard was also expected to take in to account the 335 
differences in matrix effect between the two matrices, as well as any small losses that 336 
occurred due to non-specific binding that occurred in the injection plate. Whilst the buffer 337 
solution selected as the surrogate matrix is of quite a different nature to the plasma samples, 338 
assays for small [35] and large molecules [19]  have been successfully validated using such 339 
an approach, and the validation experiments described later in this manuscript fully assess 340 
the assay’s performance.  It was decided to proceed with this approach rather than 341 
investigate alternative matrices such as charcoal stripped plasma.   It has been suggested 342 
that when a surrogate matrix approach is used that aliquots of the authentic matrix 343 
containing the endogenous analyte should be used as QC MED samples and QC HIGH 344 
samples should be prepared by spiking analyte in addition to this endogenous level [35].QC 345 
LOW samples are then made by diluting authentic matrix with surrogate matrix, and  346 
QC LLOQ samples prepared in pure surrogate matrix. Unfortunately this strategy cannot be 347 
used for glucagon quantitation due to its relatively low endogenous levels (LLOQ to 3x 348 
LLOQ). It was therefore decided to construct QC LOW using surrogate matrix, and QC MED 349 
and QC HIGH samples were prepared by spiking analyte on top of the endogenous level in 350 
authentic matrix. Due to the low endogenous levels it was decided to limit the LOW level to 2 351 
x LLOQ (rather than the 3x LLOQ typically used [18]. 352 
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Human plasma (K3 EDTA) from a commercial supplier was analysed using the assay to 353 
determine its suitability as an authentic matrix. As shown in Supplemental Figure 4 such 354 
plasma has a significantly raised background compared to plasma collected from volunteers 355 
in house. This may be a result of the lack of stabiliser upon collection, the age of the plasma 356 
and/or storage conditions. The raised background makes it unsuitable for the construction of 357 
QC samples, and therefore it was decided to use plasma collected in house as the integrity 358 
of these samples could be ensured.  Similarly, sample collection and storage regimes for 359 
any clinical samples should be carefully controlled to ensure their integrity. 360 
Validation  361 
The precision and accuracy of the method was determined by analysis of replicate (n=6) QC 362 
samples at four different concentrations (25, 50, 100 and 750 pg/mL). Precision and 363 
accuracy was assessed within a batch (intra-batch, n = 6 replicates) and between batches 364 
(inter-batch, 3 batches). The intra- and inter-assay precision did not exceed 20%, nor did the 365 
intra- and inter-assay accuracy demonstrating the method was performing robustly 366 
(Supplemental Table 1). No carryover after high calibration standards was observed and no 367 
potentially interfering peaks were observed during the selectivity assessment. The 10-fold 368 
dilution of an over range QC sample (7500 pg/mL) with control plasma was used to 369 
demonstrate the absence of dilution effects (Supplemental Table 2). 370 
  371 
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 372 
The analogue Internal standard (IS) compensated for differences in suppression observed 373 
by the analyte in different matrices, with mean matrix factor (MF) ratios being 1.08 and 1.05 374 
at the medium and high level; a perfect correction would have a ratio of 1 (Supplemental  375 
Table 3). 376 
Recovery was assessed across three different batches with a minimum of 3 replicates at 377 
each level. In order to investigate whether the nature of the matrix affected recovery it was 378 
assessed from; samples where the analyte was spiked into control matrix then immediately 379 
extracted, samples where the analyte was spiked into 3 freshly acquired matrix pools then 380 
immediately extracted, and finally from samples where the analyte was spiked into matrix 381 
then stored for a week at -80 C before extraction (Supplemental Table 4). No significant 382 
difference between these experiments was observed, which gave an average analyte 383 
recovery of 51.2%  384 
  385 
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Acceptable sensitivity is usually demonstrated by assessing whether the analyte response at 386 
the LLOQ level is at least 5 times [18] the average response due to background noise 387 
(Figure 2), which was the case for all accepted batches. It is then assumed that an unknown 388 
sample at the LLOQ concentration would also have a similarly acceptable response. 389 
However, this will not necessarily be the case for surrogate matrix assays, due to differences 390 
in the recovery and matrix factor between the surrogate and authentic matrices. By taking 391 
into account the mean analyte recovery (51.2%) and mean matrix factor (0.746) for our 392 
assay, it was calculated that signal-to-noise (S/N) at the LLOQ should be at least 13.1 to 393 
ensure that S/N for an authentic sample at the LLOQ level 5 (assuming an unchanged 394 
background level). This criterion was not formally part of our validation, but it was met by all 395 
accepted batches. 396 
 397 
 398 
Figure 2- Representative LLOQ for glucagon in plasma (25 pg/mL) surrogate matrix chromatogram 399 
demonstrating a signal-to-noise of ≥ 13.1  400 
Although we used Aprotinin, a degree of glucagon instability within human plasma was 401 
apparent and most experiments gave results outside the acceptance criteria of 20% of the 402 
nominal concentration (Table 1). Even if 0 hr concentrations were used, to take into account 403 
any assay bias or preparation differences, many results remain outside 20% of this 404 
concentration. Glucagon plasma samples were found to be within 23.7% of their nominal 405 
concentrations following storage at the extraction temperature (+4C) for 6 hours 20 406 
minutes, and within 21.4% of their 0 hr concentration following storage for 75 days at -20C, 407 
or within 20.2% following storage for 51 days at -80C. Greater instability was observed 408 
following multiple freeze-thaw cycles, and these should therefore be minimised during 409 
analysis. The accuracy of the method is therefore limited by the sub-optimal sample 410 
stabilisation procedure.  The effect of such pre-analytical parameters has been described by 411 
others [36] , and  future assay development should include an evaluation of these. For 412 
example, stability would likely be improved if specific DPP-IV inhibitors were used [37], 413 
rather than the broad serine protease inhibitor Aprotinin.  414 
 415 
Analyte Transition 
S/N= 19 
Internal standard 
transition 
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As stability in Human K3 EDTA plasma with Aprotinin stabilisation did not pass our 416 
acceptance criteria, the method is described as qualified, rather than validated. However, the 417 
instability was moderate, and the data generated is likely to “fit for purpose” for many 418 
applications. 419 
 420 
Key Terms 421 
Validated assay –An assay where experiments based on those described in the USA FDA 422 
Guidance for Industry: Bioanalytical Method Validation (2001) and those described in the 423 
EMA Guideline on Bioanalytical Method Validation (2012) meet their prospectively defined 424 
acceptance criteria. 425 
Qualified assay – An assay where not all of the validation experiments described in the 426 
guidance have been assessed or have passed their prospectively defined acceptance 427 
criteria. However the assay may still be considered “fit-for-purpose”. 428 
Fit- for-purpose assay- An assay where its performance characteristics have been assessed 429 
and are reliable for the intended application. For example, a biomarker assay  which is used 430 
to assess  a sole pharmacodynamic end point requires  better performance characteristics 431 
than an assay used as part of a panel of measurements. 432 
 433 
Table 1- Glucagon stability data; Freezer and, extraction temperature stability of glucagon in plasma 434 
Nominal  
Concentration 
 
Stability of Glucagon in Aprotinin stabilised human plasma (K3 EDTA)  
+4 C - 20 C 
C 
-80 C 
6 hr 20 min 
 
4 F/T 11days 75days 4 F/T 7days 11days 51Days 64days  
 MED  
(100 pg/mL) 
  
Mean Measured Conc. (pg/mL) 76.9 54.8 83.6 81.8 75.0 89 - 81.4 71.4 
SD 4.23 6.48 6.75 5.35 5.23 5.16 - 8.97 4.16 
%CV 5.5 11.8 8.1 6.5 7.0 5.8 - 11 5.8 
% Stability (c.f. nominal) 76.9 54.8 83.6 81.8 75.0 89.0 - 81.4 71.4 
% Stability (c.f. 0hr) - 51.6 85.5 83.7 70.6 91.0 - 81.7 71.7 
HIGH 
(750 pg/mL)  
 
  
  
  
Mean Measured Conc. (pg/mL) 572 332 581 526 464 530 615 533 445 
SD 9.50 25.3 21.9 52.8 57.7 11.9 32.7 46 30.6 
%CV 1.7 7.6 3.8 10 12.4 2.2 5.3 8.6 6.9 
% Stability (c.f. nominal) 76.3 44.3 77.5 70.1 61.9 70.7 82.0 71.1 59.3 
% Stability (c.f. 0hr) 85.6 41.5 86.8 78.6 58.0 79.2 91.9 79.8 66.7 
 435 
SD Standard deviation CV Coefficient of variation  - No data available 436 
% Stability (c.f. nominal) = 100 * mean measured concentration / nominal concentration  437 
% Stability (c.f. 0 hr) = 100 * mean measured concentration / mean measured 0hr concentration  438 
Statistics are of n=6 replicates, expect for 64 days (-80C), which have n=4 and n=5 replicates at the MED and HIGH level respectively.  439 
The ability to re-inject extracts was demonstrated after storage at +4°C for 6 days 440 
(Supplemental Table 5). The stability of stock and working solutions of glucagon, which were 441 
stored at -20 C when not in use, was demonstrated for 67 and 163 days respectively 442 
(Supplemental Table 6).  443 
The stability of glucagon in Aprotinin stabilised whole blood following storage on ice for 1 444 
hour was found to be within acceptance criteria (Supplemental Table 7).  445 
 446 
Haemolysed samples (plasma spiked with 3% whole blood) contained a large neighbouring 447 
peak, and did not pass acceptance criteria, demonstrating haemolysed samples cannot be 448 
accurately quantified using this method (Supplemental Figure 5). The presence of 449 
hyperlipidaemic plasma did not significantly affect the quantitation of glucagon 450 
(Supplemental Table 8).  451 
 452 
 453 
Using the qualified LC-MS/MS method to assess endogenous glucagon concentrations from 454 
volunteers 455 
Plasma was collected from 12 healthy males and 12 healthy females and glucagon levels 456 
determined using the qualified LC-MS/MS method. As shown in Table 2 levels agreed well 457 
with the 25-80 pg/mL range determined by RIA [1]. Chromatograms from samples which 458 
gave glucagon concentrations above the LLOQ showed good signal to noise ratios (Figure 459 
3). Some samples which gave glucagon concentrations below the LLOQ showed 460 
integratable peaks (Figure 3) and their approximate concentrations were determined by 461 
extrapolation (Table 2) 462 
Table 2- Glucagon concentrations from healthy volunteers.  463 
Male 
Volunteer 
ID 
Measured 
glucagon 
concentration 
(pg/mL) 
Female 
Volunteer 
ID 
Measured 
glucagon 
concentration 
(pg/mL) 
M1 34.2 F1 BLQ (10.4) 
M2 27.4 F2 BLQ (16.5) 
M3 BLQ (16.0) F3 BLQ (12.1) 
M4 31.2 F4 41.6 
M5 50.2 F5 BLQ (17.7) 
M6 63.0 F6 44.4 
M7 BLQ (21.3) F7 29.6 
M8 53.7 F8 59.5 
M9 40.4 F9 31.7 
M10 39.4 F10 BLQ 
M11 BLQ (20.0) F11 BLQ 
M12 153 F12 BLQ 
BLQ – Below limit of quantitation (25 pg/mL). Extrapolated values are in parenthesis. No integratable peaks were observed for 464 
F10, F11, F12. No haemolysis was observed in the samples.  465 
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       466 
 467 
Figure 3 Chromatograms showing endogenous levels of glucagon in plasma samples from healthy 468 
volunteers.M3 (a),M8 (b), F8 (c), and F9 (d)  469 
 470 
The majority of samples (58%) gave glucagon concentrations above the 25 pg/mL qualified 471 
LLOQ, demonstrating the assay’s utility for endogenous level analysis. However as glucagon 472 
concentrations in some individual plasmas were very close to, or below, this level, for 473 
subsequent analysis we decided to include additional standards and QCs at the 10 and 15 474 
pg/mL concentrations. These allowed assessment of whether a lower LLOQ could be 475 
achieved on a batch to batch basis.  The acceptable LLOQ was experimentally determined 476 
by ensuring that its performance was within acceptance criteria (signal to noise >5, and CV 477 
and RE (<20%).   478 
To assess whether quantitation was reproducible at the endogenous level, samples 479 
containing endogenous glucagon were pooled together, and analysed multiple times in 3 480 
different batches (n=6 replicates in each batch) using the approach above. An overall mean 481 
of 26.5 pg/mL was observed with an overall CV of 19.8%, demonstrating reproducible 482 
quantification at the endogenous level (Supplemental Table 9).  QCs (n=6 replicates) 483 
consistently performed within 20% (RE and CV) at the 15 pg/mL level in each of the 3 484 
batches, and were within 20% (RE and CV) at the 10 pg/mL level in 2 out of the 3 batches 485 
(Supplemental Table 10). This allowed the LLOQ to be reduced from the 25 pg/mL level in 486 
the qualified assay, to increase the proportional of quantifiable concentrations.   487 
a) M3 
(BLQ) 
 
b) M8  
(53.7 pg/mL) 
 
d) F9  
(31.7 pg/mL) 
 
c) F8  
(59.5 
pg/mL) 
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LC-MS/MS vs. RIA assays for physiological study samples 488 
Plasma samples (n= 117) were collected from a physiological study involving the infusion of 489 
glucagon. 100 of these samples were analysed using our LC-MS/MS assay and 105 490 
samples using the established RIA assay. Both assays contained QC samples, which 491 
performed within their established acceptance criteria.  492 
Bland-Altman analysis of the 88 common samples shows that the mean bias of the LC/MS-493 
MS assay versus the RIA is +45.06 pg/ml with 95% bias confidence intervals of -358.5 to 494 
448.6 pg/ml. Inspection of the plot (Figure 4 a) shows that there is a concentration-495 
dependent positive bias, particularly at values above 600 pg/ml, which is also evident in the 496 
scatter plot (Figure 4 b)   This would be expected if the RIA assay was suffering from the 497 
hook effect at higher concentrations, which has been reported for other biomarkers such as 498 
calcitonin [38]. 499 
 500 
 501 
 502 
Figure 4a – Bland-Altman plot and b) scatter plot comparing performance of LC-MS/MS and RIA 503 
methods for glucagon.  504 
 505 
RIA and LC-MS/MS assays produced pharmacokinetic (PK) profiles of similar shapes, which 506 
fitted with expectations from the nature of the study (Figure 5). It is therefore not possible to 507 
determine which assay gives the “right” answer, and the approaches should be regarded as 508 
complementary. 509 
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510 
 511 
Figure 5- A selection of PK profiles from RIA assay concentrations (red squares) and LC-MS/MS 512 
method concentrations (blue diamonds).Y axis units are pg/mL. See supplemental information Figure 513 
6 for the complete set of 9 profiles  514 
 515 
Conclusion 516 
The developed procedure is the first peer reviewed LC-MS/MS method capable of 517 
quantifying endogenous levels of glucagon in human plasma. Glucagon levels from healthy 518 
volunteers agreed well with the range expected from RIA assays. Our method avoids the 519 
radioactivity (and precautions this requires) associated with RIA assays, has a shorter 520 
extraction time and good precision and accuracy.  521 
The 25 pg/mL LLOQ in our qualified assay is a considerable improvement over the lowest 522 
LC-MS/MS LLOQ previously reported (250 pg/mL) in the peer reviewed literature [11]. A 10 523 
pg/mL LLOQ has been reported in a conference presentation [14], using a highly sensitive 524 
QTRAP mass spectrometer. We were on occasion able to see such levels using our 525 
instrument, although we performed the qualification using a 25 pg/mL LLOQ to improve 526 
assay robustness. Transferring this assay on to a more modern instrument may enable the 527 
LLOQ of 10 pg/mL to be achieved routinely. Our 2D extraction procedure was key to 528 
achieving such sensitivity, by reducing matrix suppression, background noise, and 529 
interferences. To our knowledge this is the first time protein precipitation and size exclusion 530 
SPE have been combined for such a purpose for high throughput peptide analysis. Our 531 
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surrogate matrix approach, using a mixture of non-extracted surrogate matrix STDs and QCs 532 
and extracted authentic matrix QCs, is also a novel strategy for endogenous peptide 533 
analysis.  534 
Bland-Altman analysis shows a mean positive bias of the LC/MS-MS method versus the RIA 535 
that appears to be a concentration-dependent, as would be expected if the RIA was suffering 536 
from the hook effect at higher concentrations. The PK profiles from both assays were similar 537 
shapes, and both profiles fitted with the nature of the physiological study suggesting the 538 
methods are complementary. 539 
The assay‘s performance has been qualified using experiments described in the latest EMA 540 
[18]  and FDA [17] guidance and in accordance to the principles of GCP [23].  541 
 542 
  543 
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Executive Summary 544 
Introduction 545 
 Published LC-MS/MS methods are not sensitive enough to quantify endogenous 546 
levels of glucagon. 547 
 Endogenous compounds, such as glucagon, can be quantified using either a 548 
standard addition, surrogate analyte, or a surrogate matrix approach. 549 
 We favoured the surrogate matrix approach as it avoids extrapolation and is 550 
described in the EMA Guideline on bioanalytical method validation. 551 
Results and Discussion 552 
Method development 553 
 Extensive optimisation has generated the most sensitive LC-MS/MS method for 554 
glucagon quantitation in the peer reviewed literature. 555 
 A novel 2D extraction technique, combining protein precipitation with size exclusion 556 
hydrophobic (SEH) SPE, was key to achieving such sensitivity, by reducing matrix 557 
suppression, background noise, and interferences. 558 
 Quantitation used a mixture of non-extracted surrogate matrix STDs and QCs and 559 
extracted authentic matrix QCs. Such approach is a novel strategy for endogenous 560 
peptide analysis. 561 
 562 
Validation 563 
 Validation experiments performed were based on those described in the latest EMA 564 
and FDA guidelines. 565 
 Most experiments, including the precision and accuracy of the method, were within 566 
the prospectively defined acceptance criteria. 567 
 However, a degree of plasma sample instability was apparent, and it fell outside of 568 
our prospectively defined acceptance criteria.  569 
 The assay is therefore described as qualified, over the range 25 – 1000 pg/mL, 570 
rather than validated. The assay will however be fit-for-purpose for many 571 
applications. 572 
 573 
  574 
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Using the qualified LC-MS/MS method to assess endogenous glucagon concentrations from 575 
volunteers 576 
 Glucagon levels in healthy volunteers measured by LC-MS/MS showed good 577 
agreement with literature values determined by RIA. 578 
 Assessment of assay performance at the 10 and 15 pg/mL levels allowed the assay 579 
LLOQ to be lowered from 25 pg/mL on a batch to batch basis. 580 
 Reproducible quantitation at the endogenous glucagon level was demonstrated. 581 
 582 
LC-MS/MS vs. RIA assays for physiological study samples 583 
 Bland-Altman analysis shows a concentration-dependent positive bias of the LC/MS-584 
MS assay versus an RIA, with a mean bias of +45.06 pg/mL 585 
 Both assays produced similar PK profiles, both of which were feasible considering 586 
the nature of the study, and the methods should be regarded as complementary. 587 
 588 
 589 
 590 
Future Perspectives 591 
We believe that experimentally demanding or troublesome immunoassays, such as the 592 
glucagon RIA assay, will increasingly become replaced with LC-MS/MS based 593 
methodologies to circumvent issues with cross reactivity, increase sample throughout and 594 
avoid the use of radioactivity. To achieve the low LLOQs often required we also believe that 595 
approaches such as 2D extraction will become more commonly used. For regulated 596 
bioanalytical studies of endogenous compounds, strategies such as surrogate matrix 597 
quantitation, which avoids the need to extrapolate the calibration curve, will become the 598 
favoured approach.  599 
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